Dyadic International Inc. ( (DYAI) ) has released its Q4 earnings. Here is a breakdown of the information Dyadic International Inc. presented to its investors.
Dyadic International Inc. is a biotechnology company specializing in the large-scale production of proteins for vaccines, therapeutics, and non-pharmaceutical applications such as food and nutrition. The company leverages its proprietary microbial protein production platforms, C1 and Dapibus™, to drive innovation and efficiency in these sectors.
In its 2024 year-end financial report, Dyadic International Inc. announced a strong revenue performance, highlighted by approximately $1.9 million in milestone and license revenue. The company also secured up to $7.5 million in grants from CEPI and the Gates Foundation to accelerate the development of its C1 platform for faster and more cost-effective vaccine and antibody production.
Key financial metrics revealed a total revenue increase to approximately $3.5 million, driven by significant license revenue. The company reported a decrease in research and development costs, contributing to a reduced net loss of approximately $5.8 million compared to the previous year. Dyadic’s strategic focus on non-pharmaceutical market segments and collaborations with global organizations has bolstered its commercial pipeline, with several products nearing market launch.
Looking ahead, Dyadic International Inc. remains committed to expanding its C1 and Dapibus™ platforms across alternative proteins, and human and animal health sectors. With a growing network of partnerships and increased funding support, the company is well-positioned to drive innovation, enhance global accessibility, and reduce manufacturing costs, aiming to deliver sustained value for its investors and stakeholders.